Readily Diagnostics
Readily Diagnostics (founded 2022 as a university spin-out) develops rapid, instrument-free molecular diagnostics for infectious disease. Their platform combines ligation-dependent padlock probes with isothermal rolling circle amplification and microfluidic integration to provide multiplex pathogen detection with visual or fluorescence readouts. Current offerings include research-use microtiter plate assays and instrument-free microfluidic chips intended for near-patient and laboratory use.
Industries
Nr. of Employees
small (1-50)
Products
Readily Clinic (microfluidic chip format) - Research Use Only
Credit-card-sized microfluidic molecular test configured for instrument-free, near-patient detection of multiple pathogens from the same sample; visual or optional fluorescence readout.
Readily Research (microtiter plate format) - Research Use Only
Standard microtiter plate molecular assay configured for laboratory throughput; supports fluorescence readout and multiplex detection of viruses and variants.
Readily Clinic (microfluidic chip format) - Research Use Only
Credit-card-sized microfluidic molecular test configured for instrument-free, near-patient detection of multiple pathogens from the same sample; visual or optional fluorescence readout.
Readily Research (microtiter plate format) - Research Use Only
Standard microtiter plate molecular assay configured for laboratory throughput; supports fluorescence readout and multiplex detection of viruses and variants.
Services
Supply of start kits for evaluation (microfluidic chips or plates) with one day of support to integrate assays into research workflows.
Supply of start kits for evaluation (microfluidic chips or plates) with one day of support to integrate assays into research workflows.
Expertise Areas
- Molecular diagnostics
- Point-of-care / near-patient testing
- Microfluidics
- Assay development and multiplexing
Key Technologies
- Padlock probe-based target recognition
- Rolling circle amplification (RCA)
- Isothermal amplification
- Microfluidic chip-based assays
News & Updates
Selected as one of the top semi-final companies to pitch at TECHARENA Founder-pitch competition (Founder stage at Strawberry Arena, Stockholm).
Exhibited at The Global Laboratory Medicine Community conference in Chicago (ADLM 2024).
Granted funding from the Bio-X Accelerate Program to advance development and market introduction of next-generation rapid diagnostic tests for respiratory diseases.
Completed a €1.6 million capital round led by founders and joined by external investors to support company development.
Received a regional award recognizing companies in Uppsala County with strong growth potential.
Awarded an innovations project recognition together with academic collaborators.
Selected as one of the top semi-final companies to pitch at TECHARENA Founder-pitch competition (Founder stage at Strawberry Arena, Stockholm).
Exhibited at The Global Laboratory Medicine Community conference in Chicago (ADLM 2024).
Granted funding from the Bio-X Accelerate Program to advance development and market introduction of next-generation rapid diagnostic tests for respiratory diseases.
Completed a €1.6 million capital round led by founders and joined by external investors to support company development.
Received a regional award recognizing companies in Uppsala County with strong growth potential.
Awarded an innovations project recognition together with academic collaborators.